BridgeBio Pharma, Inc. 4

Director Andrea Ellis of BridgeBio Pharma, Inc. exercised an option and sold 17,167 shares of common stock for about $1.44 million under a Rule 10b5-1 plan, leaving her with 22,579 shares directly owned.

On July 9, 2026, BridgeBio Pharma, Inc. director Andrea Ellis exercised a stock option for 17,167 shares of common stock at an exercise price of $16.75 per share and immediately sold the same 17,167 shares at $84.00 per share pursuant to a pre-arranged Rule 10b5-1 trading plan, resulting in an approximate gross sale value of $1.44 million and an option exercise cost of about $0.29 million. Following these transactions, Ellis reported direct ownership of 22,579 shares of BridgeBio common stock, down from 39,746 shares before the sale (all values based on the prices disclosed in the Form 4). The option exercised was part of a grant that vests over three years and is scheduled to expire on June 21, 2033, with the Form 4 footnote confirming routine, pre-planned disposition activity tied to board service compensation.

Filing Facts

CIK

1743881

Ticker

BBIO

Form

4

Source Type

fda

Accession

0001470831-26-000709

Alert Tier

7